Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
Cardiology
•
Preventive Cardiology
•
Primary Care
How do you factor in a positive family history of premature CAD into ASCVD risk estimation?
Do you use other risk prediction calculators instead?
Related Questions
What is your approach to statin and/or PCSK9i initiation and counseling in a patient who has an HDL above 100, LDL within normal range, but markedly elevated calcium score exceeding 1000?
When would you consider long-term cardiac monitoring to look for atrial fibrillation in patients with mitral stenosis given their baseline elevated risk for atrial fibrillation and thrombosis?
How should we approach the recommendation of intermittent fasting for weight loss in patients with pre-existing cardiovascular conditions, given the observed association of increased CV mortality with eating durations of less than 8 hrs?
Is there a role for routine stress testing in intermediate-high risk CAD patients with a significantly elevated coronary calcium score who are otherwise asymptomatic?
What are your thoughts on the applicability and utility of the PREVENT equation and how it compares to the PCE for ASCVD risk assessment?
How do you decide between obtaining routine, outpatient ETT versus stress TTE when screening for CAD, especially given insurance company preference on ETTs?
How do you counsel patients with metabolic syndrome who decline statin therapy and have low coronary calcium scores regarding their long term CVD risk?
Would you prescribe a GLP-1 receptor agonist for an obese patient with low to moderate cardiovascular risk but a high CAC score?
When would you consider ordering additional testing such as hs-CRP, lipoprotein A levels, or CAC scoring to further risk stratify otherwise healthy pre-menopausal women with a prior history of pregnancy-related hypertension, diabetes, or premature births?
Would you consider adding niacin to the lipid lowering regimen in statin-intolerant patients who cannot afford PCSK9i or bempedoic acid?
